Stock Price Quote

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE933.40-26.15 (-2.73 %)
PREV CLOSE ( ) 959.55
OPEN PRICE ( ) 958.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 106129
TODAY'S LOW / HIGH ( )914.05 958.55
52 WK LOW / HIGH ( )482.55 1031.3
NSE933.50-25.95 (-2.7 %)
PREV CLOSE( ) 959.45
OPEN PRICE ( ) 958.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 933.50 (245)
VOLUME 3433345
TODAY'S LOW / HIGH( ) 914.50 958.95
52 WK LOW / HIGH ( )484.95 1031.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-05 1995
Management Info
Pankaj R Patel - Chairman Sharvil P Patel - Managing Director
Registered Office

Address Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone 079-71800000 / 48040000

Email dhavalsoni@zyduscadila.com

Website www.zyduscadila.com

Registrars Details
Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE, MCX

NEWS

24Apr USFDA concludes inspection at Zydus Li
United States Food and Drug Administration (USFDA) has concluded the ins..
24Apr Zydus Lifesciences informs about discl
Zydus Lifesciences has informed that the USFDA conducted an inspection a..
23Apr Zydus Lifesciences gets nod for new dr
Zydus Lifesciences has received approval from National Medical Products..
23Apr Zydus Lifesciences edges higher on get
Zydus Lifesciences is currently trading at Rs. 960.45, up by 1.00 points..
22Apr Zydus Lifesciences launches Mirabegron
Zydus Lifesciences has launched Mirabegron Extended-Release Tablets, 25..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit450415292
Gross Profit 5743 20322
Operating Profit 805930028
Net Sales 2371387316

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2621.00 (5.75%)
M.Cap ( in Cr)1619.26
Glaxosmithkline Phar (BSE)
peergroup  2079.80 (7.06%)
M.Cap ( in Cr)35233.07
TTK Healthcare (BSE)
peergroup  1591.35 (5.77%)
M.Cap ( in Cr)2248.63
Cipla (BSE)
peergroup  1398.80 (3.79%)
M.Cap ( in Cr)112938.41
Torrent Pharma (BSE)
peergroup  2685.00 (1.85%)
M.Cap ( in Cr)90872.60

Shareholding Pattern

PROMOTERS 74.98%
MUTUAL FUNDS/UTI 6.71%
NON-INSTITUTION 6.66%
FI/BANKS/INSURANCE 5.74%
GOVERNMENT 0%
FII 0%

About Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 933.4. Its current market capitalisation stands at Rs 93921.88 Cr. In the latest quarter, company has reported Gross Sales of Rs. 87222 Cr and Total Income of Rs.95560 Cr. The company's management includes Dhaval N Soni, Mukesh M Patel, Upasana Konidela, Akhil Monappa, Apurva S Diwanji, Dharmishta N Raval, Bhadresh K Shah, Nitin R Desai, Ganesh N Nayak, Sharvil P Patel, Pankaj R Patel.

It is listed on the BSE with a BSE Code of 532321 , NSE with an NSE Symbol of ZYDUSLIFE and ISIN of INE010B01027. It's Registered office is at Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar HighwayAhmedabad-382481, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Mukesh M Shah & Co, RR Patel & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.